Paul Tudor Jones's RCUS Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 208,639 shares of Arcus Biosciences, Inc. (RCUS) worth $4.97 M, representing 0.01% of the portfolio. First purchased in 2018-Q1, this medium-term investment has been held for 18 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in RCUS, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 208,639 shares. Largest reduction occurred in Q3 2020, reducing 66,529 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Arcus Biosciences (RCUS) Holding Value Over Time
Track share changes against reported price movement
Quarterly Arcus Biosciences (RCUS) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +208,639 | New Buy | 208,639 | $23.83 |
| Q2 2025 | -53,466 | Sold Out | 0 | $0.00 |
| Q1 2025 | +10,498 | Add 24.43% | 53,466 | $7.85 |
| Q4 2024 | -2,682 | Reduce 5.88% | 42,968 | $14.89 |
| Q3 2024 | +45,650 | New Buy | 45,650 | $15.29 |
| Q4 2023 | -28,173 | Sold Out | 0 | $0.00 |
| Q3 2023 | +28,173 | New Buy | 28,173 | $17.95 |
| Q4 2021 | -41,200 | Sold Out | 0 | $0.00 |
| Q3 2021 | -12,857 | Reduce 23.78% | 41,200 | $34.88 |
| Q2 2021 | +46,796 | Add 644.48% | 54,057 | $27.45 |
| Q1 2021 | -28,296 | Reduce 79.58% | 7,261 | $28.10 |
| Q4 2020 | +35,557 | New Buy | 35,557 | $25.96 |
| Q3 2020 | -66,529 | Sold Out | 0 | $0.00 |
| Q2 2020 | +66,529 | New Buy | 66,529 | $24.74 |
| Q1 2020 | -13,423 | Sold Out | 0 | $0.00 |
| Q4 2019 | +13,423 | New Buy | 13,423 | $10.13 |
| Q2 2018 | -27,723 | Sold Out | 0 | $0.00 |
| Q1 2018 | +27,723 | New Buy | 27,723 | $15.44 |
Paul Tudor Jones's Arcus Biosciences Investment FAQs
Paul Tudor Jones first purchased Arcus Biosciences, Inc. (RCUS) in Q1 2018, acquiring 27,723 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Arcus Biosciences, Inc. (RCUS) for 18 quarters since Q1 2018.
Paul Tudor Jones's largest addition to Arcus Biosciences, Inc. (RCUS) was in Q4 2025, adding 208,639 shares worth $4.97 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 208,639 shares of Arcus Biosciences, Inc. (RCUS), valued at approximately $4.97 M.
As of the Q4 2025 filing, Arcus Biosciences, Inc. (RCUS) represents approximately 0.01% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Arcus Biosciences, Inc. (RCUS) was 208,639 shares, as reported at the end of Q4 2025.